Cargando…

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

BACKGROUND: The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). METHODS: Sera from patients with IBD and RA with or...

Descripción completa

Detalles Bibliográficos
Autores principales: Goncalves, Joao, Myung, Gihyun, Park, MinJeong, Jeong, Deokyoon, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893927/
https://www.ncbi.nlm.nih.gov/pubmed/31839806
http://dx.doi.org/10.1177/1756284819891081
_version_ 1783476301186727936
author Goncalves, Joao
Myung, Gihyun
Park, MinJeong
Jeong, Deokyoon
Ghil, Jeehoon
author_facet Goncalves, Joao
Myung, Gihyun
Park, MinJeong
Jeong, Deokyoon
Ghil, Jeehoon
author_sort Goncalves, Joao
collection PubMed
description BACKGROUND: The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). METHODS: Sera from patients with IBD and RA with or without antibodies to adalimumab (ATA+ or ATA–, respectively) were tested for cross-reactivity with SB5 and ADL. Functional inhibition of tumor necrosis factor-α binding was measured. Sera from patients with antibodies to reference infliximab (ATI+) were examined for cross-reactivity to SB5. Sera were tested by enzyme-linked immunosorbent assay. RESULTS: All 30 anti-ADL ATA+ sera from patients with IBD and all 4 anti-SB5 ATA+ sera from patients with RA were cross-reactive with ADL and SB5 (range of mean concentrations: IBD, 20.99–21.31 μg/ml; RA, 16.46–17.48 μg/ml). In general, there was no significant difference between mean ATA titers. A strong correlation was detected in all ATA+ samples (rho = 0.997 to >0.999; p < 0.001 each). However, ATA– sera were not reactive to either ADL or SB5. anti-ADL ATA+ sera similarly neutralized functional activity of ADL and SB5; no functional inhibition was observed with ATA– sera. ATI+ sera did not cross-react with SB5. CONCLUSIONS: ADL and SB5 show cross-immunogenicity in sera from patients with IBD or RA, supporting shared immune-dominant epitopes. ATI+ sera did not cross-react with SB5, suggesting different immunogenic epitopes between infliximab and SB5.
format Online
Article
Text
id pubmed-6893927
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-68939272019-12-13 SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis Goncalves, Joao Myung, Gihyun Park, MinJeong Jeong, Deokyoon Ghil, Jeehoon Therap Adv Gastroenterol Original Research BACKGROUND: The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). METHODS: Sera from patients with IBD and RA with or without antibodies to adalimumab (ATA+ or ATA–, respectively) were tested for cross-reactivity with SB5 and ADL. Functional inhibition of tumor necrosis factor-α binding was measured. Sera from patients with antibodies to reference infliximab (ATI+) were examined for cross-reactivity to SB5. Sera were tested by enzyme-linked immunosorbent assay. RESULTS: All 30 anti-ADL ATA+ sera from patients with IBD and all 4 anti-SB5 ATA+ sera from patients with RA were cross-reactive with ADL and SB5 (range of mean concentrations: IBD, 20.99–21.31 μg/ml; RA, 16.46–17.48 μg/ml). In general, there was no significant difference between mean ATA titers. A strong correlation was detected in all ATA+ samples (rho = 0.997 to >0.999; p < 0.001 each). However, ATA– sera were not reactive to either ADL or SB5. anti-ADL ATA+ sera similarly neutralized functional activity of ADL and SB5; no functional inhibition was observed with ATA– sera. ATI+ sera did not cross-react with SB5. CONCLUSIONS: ADL and SB5 show cross-immunogenicity in sera from patients with IBD or RA, supporting shared immune-dominant epitopes. ATI+ sera did not cross-react with SB5, suggesting different immunogenic epitopes between infliximab and SB5. SAGE Publications 2019-12-04 /pmc/articles/PMC6893927/ /pubmed/31839806 http://dx.doi.org/10.1177/1756284819891081 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Goncalves, Joao
Myung, Gihyun
Park, MinJeong
Jeong, Deokyoon
Ghil, Jeehoon
SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
title SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
title_full SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
title_fullStr SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
title_full_unstemmed SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
title_short SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
title_sort sb5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893927/
https://www.ncbi.nlm.nih.gov/pubmed/31839806
http://dx.doi.org/10.1177/1756284819891081
work_keys_str_mv AT goncalvesjoao sb5showscrossimmunogenicitytoadalimumabbutnotinfliximabresultsinpatientswithinflammatoryboweldiseaseorrheumatoidarthritis
AT myunggihyun sb5showscrossimmunogenicitytoadalimumabbutnotinfliximabresultsinpatientswithinflammatoryboweldiseaseorrheumatoidarthritis
AT parkminjeong sb5showscrossimmunogenicitytoadalimumabbutnotinfliximabresultsinpatientswithinflammatoryboweldiseaseorrheumatoidarthritis
AT jeongdeokyoon sb5showscrossimmunogenicitytoadalimumabbutnotinfliximabresultsinpatientswithinflammatoryboweldiseaseorrheumatoidarthritis
AT ghiljeehoon sb5showscrossimmunogenicitytoadalimumabbutnotinfliximabresultsinpatientswithinflammatoryboweldiseaseorrheumatoidarthritis